Neurology Central

Neuro Central on Instagram

Click the links below to discover the full articles.
Haven’t followed us yet? Navigate here to keep up-to-date with our Instagram journey.

Neuro Central Spotlight survey on brain organoids
Do you work with brain organoids? Why not take our short survey on this now and you could be in the chance to win a free subscription to the journal, Regenerative Medicine! This survey is designed to explore the current landscape of organoids in neuroscience and neurology research.

Early-onset Alzheimer’s disease linked to high LDL cholesterol levels
In a recent study, researchers have discovered a possible link between high LDL cholesterol and early-onset Alzheimer’s disease. The results could potentially aid clinicians to understand how the disease develops and what the possible causes are, including genetic variation.

#VoicesForDementia – video campaign for World Alzheimer’s Day
In the lead up to World Alzheimer’s Day next week (21 September), we’ll be launching our video campaign on #VoicesForDementia. We’re excited to promote awareness around dementia from those affected and those working in the field – follow us on Twitter for the latest updates.

London to Le Mans – Neuro Central fundraising event
We’re extremely excited to announce our fundraising event for #WorldAlzheimersMonth! We’ll be “walking” from London to Le Mans to support our partnered charities, Alzheimer’s Research UK and the Alzheimer’s Society. You can help sponsor our teams and donate here:

FiTBI18: Frontiers in Traumatic Brain Injury
We’re excited to announce that we’ll be attending Frontiers in Traumatic Brain Injury (FiTBI18; 5–6 July, London, UK)! What are your must-see talks/posters that you’d like us to potentially cover? We’ll be live tweeting about the event on Twitter, so be sure to follow us on there for live coverage of the event.

Brain injury biomarker levels increase as a result of asymptomatic high-acceleration head impacts
Serum levels of two biomarkers associated with traumatic brain injury were found to have increased in American varsity football players following high-acceleration head impacts, researchers from the University of Michigan (MI, USA) have revealed.

Conference preparation: a sneak peek behind the scenes
Are you attending FENS2018 (Berlin, Germany) or AAIC18 (IL, USA)? You could stand a chance at winning a selection of British treats and Neuro Central pens and USBs on our spin wheel (in addition to our tote bags)! Be sure to visit us at booth #89 at FENS and booth #729 at AAIC for a chance to win.

Ask the Experts: Emerging therapies in multiple sclerosis (Part I: mechanisms, therapies and challenges)
In line with our focus this month, we’ve brought together a panel of experts to discuss emerging therapies in multiple sclerosis (MS). Take a look at Part I below including mechanisms, therapies and challenges involved in MS research.

Techniques and emerging approaches – cerebral organoids
This month we’re focusing on techniques and emerging approaches – take a look at our infographic to learn more about the use of cerebral organoids as an emerging therapy; including key research, ethical questions and future applications.

A peek into the office: World Cup sweepstake
Things are getting exciting here at Neuro Central HQ for the Fifa 2018 World Cup! Our team have picked out Denmark, Iceland, Russia, Colombia and France for the office sweepstake – will we stand a chance at winning? Keep up-to-date with our office sweepstakes by following us on Instagram here.

Alzheimer’s disease: Phase III clinical trials of lanabecestat to discontinue
Eli Lilly (IN, USA) and AstraZeneca (Cambridge, UK) have announced that they are discontinuing the global Phase III clinical trials of lanabecestat for the treatment of Alzheimer’s disease. The decision has been based on recommendations by an independent data monitoring committee.

Investigational gene therapy licensed for Parkinson’s disease: industry news round-up
This week’s industry news round-up reveals the latest updates around spinal muscular atrophy and the discontinuation of olesoxime by Roche, an investigational gene therapy licensed for Parkinson’s disease and Biogen entering an agreement to acquire TMS-007 for acute stroke.